What is Provenge?
Provenge is the brand name for sipuleucel-T, an immunotherapy used to treat advanced prostate cancer. It works by using a patient’s own immune cells, which are collected and then activated outside the body with a prostate cancer–related protein, before being reinfused to help the immune system attack prostate cancer cells [1].
Who is it for, and when is it used?
Provenge is used in men with advanced prostate cancer who have progressed despite other treatments. The therapy is designed for hormone-refractory (castration-resistant) prostate cancer, meaning the cancer continues to grow even when testosterone levels are kept low with androgen-deprivation therapy [1].
How is Provenge given (what happens during treatment)?
Treatment involves multiple steps: immune cells are collected from the patient, the cells are then processed/activated in a treatment center, and the prepared cells are reinfused back into the patient. Patients typically receive several doses as part of the treatment course [1].
What side effects are patients most likely to experience?
Because Provenge stimulates the immune system, side effects often reflect immune activation. Commonly reported effects include chills, fever, fatigue, nausea, and flu-like symptoms around the time of infusion [1]. Like other cancer therapies, it can also cause other less common adverse events; the full risk profile depends on the patient’s condition and other treatments.
Does Provenge still get used today?
Provenge is an older checkpoint-free immunotherapy option. Whether a patient is offered Provenge depends on disease stage, prior treatments, availability, and current guideline preferences compared with newer prostate cancer therapies [1].
How much does Provenge cost?
Pricing depends heavily on healthcare setting and country, and it can change over time. If you share your location and whether this is for coverage through insurance/Medicare, I can help narrow what to expect—based on typical billing structures for infused therapies. (No pricing figures are provided in the source materials I can cite here.)
---
Sources
[1] https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/types/cancer-immunotherapy-prostate-cancer-sipuleucel-t